Formation Bio

Formation Bio is an AI-native pharma company differentiated by radically more efficient drug development.

The company has built proprietary technology platforms to optimize critical aspects of clinical drug development, enabling more efficient trial design, faster trial completion, and higher quality trial data.

Formation Bio acquires clinical-stage drugs from pharmaceutical and biotech companies with the goal to develop assets faster, unlock greater value per program and ultimately accelerate access to new treatments for patients.

2025 CNBC Disruptor 50 2025 Fierce 15 Award 2024 Endpoints 11 Award